Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegtarviliase in Homocystinuria Due to CBS Deficiency
NCT05154890Phase 2Terminated
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Apr 2023
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of pegtarviliase in homocystinuria (HCU), sponsored by Spyre Therapeutics, Inc.. Started May 2021; status: terminated.
02
Drugs
pegtarviliase
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on NCT05154890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154890.